Mesa Laboratories Q1 Earnings Call Highlights

First-quarter revenue rose 1% to $60.1 million , while gross and adjusted operating margins improved significantly through cost controls, supply-chain efficiencies and favorable product mix. Operating cash flow increased to $14.7 million, and Mesa repaid $8.7 million of debt, lowering net leverage to 1.85 times. The Sterilization and Disinfection Control segment declined 3.6% organically because of fulfillment and delivery-reliability problems, not weaker demand. CEO Siddhartha Kadia is prioritizing more consistent execution and backlog reduction while maintaining quality standards. Biopharmaceutical Development grew 5% organically and Calibration Solutions increased 7.6%, but management cautioned that BPD’s recovery is still developing. Mesa expects to provide fiscal 2027 guidance with second-quarter results in November and plans to launch its next-generation Gyrolab platform in fiscal 2028. Mesa Laboratories NASDAQ: MLAB reported first-quarter fiscal 2027 revenue growth of 1%, improved operating margins and continued debt reduction, while newly appointed President and CEO Siddhartha Kadia outlined plans to address fulfillment issues in its Sterilization and Disinfection Control business and accelerate product development in Biopharmaceutical Development. Total first-quarter revenue was $60.1 million, up 1% from the prior-year period. Organic revenue also increased 1%, while core organic growth, excluding a 60-basis-point currency benefit, was 0.4%, according to Chief Financial Officer John Sakys. “Mesa is a set of durable, regulation-embedded franchises with real and growing earnings power that had fixable execution problems,” Kadia said on his first earnings call as CEO. He said the company’s near-term emphasis will be on execution, capital reallocation and debt reduction rather than acquisitions. Margins and Cash Flow Improved Gross profit rose to $39 million, or 64.9% of revenue, from 62% a year earlier. Sakys attributed the roughly 290-basis-point improvement to lower spending on third-party contracted labor and consultants, supply-chain efficiencies and favorable product mix, partly offset by lower volume in Sterilization and Disinfection Control, or SDC. Operating expenses declined 5.6% to $32 million, reflecting lower stock-based compensation and cost controls. GAAP operating income increased 129% to $7 million. Adjusted operating income increased 16.5% to $15 million, or $2.61 per diluted share. Excluding a $382,000 legal settlement, adjusted operating income was $15.4 million, representing 25.6% of revenue, compared with 21.7% in the prior-year quarter. GAAP net income was $2.8 million, or $0.49 per diluted share, down 40.3% from a year ago. Sakys said the decline was driven by a non-operating swing related primarily to unrealized foreign-currency gains and losses on an intercompany loan, rather than operating performance. Cash flow from operating activities totaled $14.7 million, an increase of $12.8 million year over year. The company ended the quarter with $30.7 million in cash and cash equivalents and repaid $8.7 million of debt, reducing net leverage to 1.85 times. Mesa is targeting net leverage of roughly 1.5 to 1.75 times by the end of fiscal 2027. SDC Delivery Reliability Remains a Focus SDC, Mesa’s largest business and 41% of quarterly revenue, generated $24.5 million in sales, down 3.6% organically. Kadia said the shortfall reflected delivery reliability and fulfillment timing rather than weakened demand. The company’s past-due backlog increased by about $1 million from its fiscal year-end level. Kadia said Mesa had reduced backlog substantially through a production push in the fourth quarter of fiscal 202...